The Conversation (0)
More Featured Articles and Inverviews
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Latest News
Latest News
Outlook Reports world
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.